KalVista Pharmaceuticals

KalVista Pharmaceuticals is a biopharmaceutical company that discovers, develops, and commercializes orally administered protease inhibitor drugs based on deep expertise in the kallikrein-kinin system. We are committed to rigorous scientific research, driven by our determination to better meet patients' therapeutic needs, starting with our first investigational product for Hereditary Angioedema (HAE), a rare genetic disorder characterized by unpredictable episodes of tissue swelling that can be life-threatening.